window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 23, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Liza

  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Kairos Pharma and Bayer to evaluate ENV-105 combination in prostate cancer

    Kairos Pharma and Bayer will evaluate ENV-105 in combination with [...]

    July 23, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Delivery & Formulation,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    Lonza expands ADC drug product capacity in Switzerland

    Lonza is expanding its commercial-scale aseptic drug product capacity in [...]

    July 23, 2026
  • Central Nervous System,Research & Development

    Brain network dynamics may better explain psychiatric symptoms than diagnoses

    Rutgers researchers found that changes in brain network dynamics were [...]

    July 22, 2026
  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics,Research & Development

    India’s CDMO market needs science, not just scale, says Lupin Manufacturing Solutions CEO

    In this exclusive interview with Liza Laws for Discover Pharma, [...]

    July 23, 2026
  • Central Nervous System,Digital & Data,Medical devices

    Natus expands AI-powered EEG analysis across Europe

    Natus has expanded access to its AI-powered EEG analysis tool [...]

    July 22, 2026
  • Advanced Therapies,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Enterome data link CD8 T-cell expansion to progression-free survival in lymphoma

    Enterome Phase 1/2 data show EO2463-induced CD8 T-cell expansion was [...]

    July 22, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    Telix starts Phase 3 trial of radiopharmaceutical therapy for renal cancer

    Telix has dosed the first patient in a Phase 3 [...]

    July 22, 2026
  • Digital & Data,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    Deep Origin computational platform identifies potent molecular glue for lymphoma treatment

    Deep Origin’s computational platform helped identify a molecular glue compound [...]

    July 22, 2026
  • Biotech & Pharma Business,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics,Research & Development

    Samsung Biologics to acquire PolyPeptide in $1.46bn deal

    Samsung Biologics has announced plans to acquire peptide CDMO PolyPeptide [...]

    July 21, 2026
  • Digital & Data,Manufacturing & Supply Chain,Research & Development

    Omniflex deploys cold chain monitoring system across 17 South African research sites

    Omniflex has deployed a cloud-based cold chain monitoring system across [...]

    July 21, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Ten-year NHS study supports focal therapy for prostate cancer with fewer side effects
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Mission Therapeutics signs US$292M deal for acute kidney injury programme
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Research & Development
  • Medicus receives FDA feedback and IRB approval for Teverelix Phase 2 urinary retention trial
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top